BIOX BIOX
Company Profile ↓Company Overview
BIOX (BIOX) is a publicly traded company listed on with a market capitalization of $23.63M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Jun 2025 Revenue of $333.34M (-28.3% YoY); net profit $-55.42M.
- Trailing 12 Months Year-on-year growth — revenue -28.3%, earnings -1396.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.49% |
| 1 Year: | -28.29% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -1,396.07% |
Stock Price Performance
| 1 Year: | -89.83% |
| 6 Months: | -37.24% |
| 3 Months: | -22.39% |
| 1 Month: | +10.64% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)53.07 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 89.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 50.10M | 74.37M | 77.44M | 73.67M | 38.20M |
| Cost of Revenue | - | 32.00M | 51.02M | 41.79M | 47.36M | 25.50M |
| Gross Profit | - | 18.10M | 23.35M | 35.64M | 26.31M | 12.70M |
| Operating Expenses | - | 12.70M | 30.26M | 27.88M | 18.49M | 17.50M |
| Operating Income | - | 5.40M | -6.92M | 7.76M | 7.82M | -4.80M |
| EBITDA | - | 14.84M | -32.88M | 9.02M | 6.84M | -7.50M |
| Interest Expense | - | 5.30M | 7.13M | 8.55M | 7.02M | 6.60M |
| Pretax Income | - | -1.20M | -44.92M | -5.37M | -1.37M | -14.10M |
| Tax Provision | - | -3.60M | 6.75M | 2.08M | 3.11M | -4.00M |
| Net Income | - | 2.60M | -47.89M | -7.33M | -183.04M | -9.00M |
| Diluted EPS | - | 0.04 | -0.70 | -0.12 | -2.88 | -0.14 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 328.46M | 419.45M | 464.83M | 333.34M |
| Cost of Revenue | 203.68M | 240.59M | 282.40M | 205.19M |
| Gross Profit | 124.78M | 178.85M | 182.43M | 128.15M |
| Operating Expenses | 80.56M | 125.62M | 138.38M | 128.91M |
| Operating Income | 44.22M | 53.23M | 44.06M | -761.90K |
| EBITDA | 38.20M | 59.73M | 56.49M | -9.76M |
| Interest Expense | 14.95M | 21.23M | 24.12M | 25.63M |
| Pretax Income | 14.06M | 19.11M | 11.07M | -57.57M |
| Tax Provision | 17.97M | -1.07M | 3.78M | 1.27M |
| Net Income | -7.20M | 18.78M | 4.28M | -55.42M |
| Diluted EPS | -0.17 | 0.30 | 0.05 | -0.83 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | 518.22M | 818.06M | 852.55M | 763.65M |
| Current Assets | 297.71M | 397.11M | 408.67M | 308.31M |
| Cash & Equivalents | 33.48M | 48.13M | 44.47M | 32.70M |
| Inventory | 126.10M | 140.57M | 126.22M | 89.99M |
| Receivables | 111.75M | 158.01M | 207.32M | 165.86M |
| Total Liabilities | 359.92M | 487.56M | 501.17M | 468.43M |
| Current Liabilities | 222.67M | 298.71M | 329.31M | 337.99M |
| Long Term Debt | 86.74M | 135.88M | 122.91M | 38.20M |
| Total Debt | 169.79M | 257.41M | 270.95M | 276.61M |
| Total Equity | 127.61M | 298.85M | 315.30M | 262.81M |
| Shares Outstanding | 45.87M | 62.80M | 62.85M | 65.63M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | 38.0% | 42.6% | 39.2% | 38.4% |
| Operating Margin % | 13.5% | 12.7% | 9.5% | -0.2% |
| Net Margin % | -2.2% | 4.5% | 0.9% | -16.6% |
| ROE % | -5.6% | 6.3% | 1.4% | -21.1% |
| ROCE % | 15.0% | 10.2% | 8.4% | -0.2% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BIOX
Bioceres Crop Solutions (BIOX) grants CFO 375,000 options under 2023 equity plan - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQUDRsazM1U2ZqMzA5TnJ3eV8yREpaWnFlRHZHNmc2UkpwY0NQdk9uU21mQVM2ckJndEZOekpFcGZyTzI4YklmZjdYM2d1UEhsTnRKUTk0QVo0dTZHaExONnZrTXRLX0NwcGlEdTgxN2MxckRoMVBPWEN0eHUwaVNZSGZGb2ZDS1pMOU1uck…
Bioceres Crop (BIOX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPNEFzbzhDR1ZzSDhDZ213MDdkM3p4YmJ1VFFGb0hWa004d0pUa0tJd0dsTXNjWU84eTl1Z3VDLTNTMW4wREhGbV9XWVo5c245OElmeFQ5WmhNVG1oR1VkeHNfVjNicm9OVHV0OUFMLWs5NGVjUTYtY0ZDemVSeG1tbmJ2bUZkbFlWOGtQUW…
Investors Don't See Light At End Of Bioceres Crop Solutions Corp.'s (NASDAQ:BIOX) Tunnel And Push Stock Down 54% - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxQOHgzNDloZENVV1gzTmlkSl9IMGwzMF84WjdYSGNxV2xOY0dRSGgyLTFONVItU2F4SEE2M1o0SVJjTkgzbzBYMjdqeThsN2c0NlRCMEo5eURrS2VVeDYweERVU0o0NmRJRnVQQk83MTZTekRJYTdDb3VSMXlvOWMwMlpJUUNDZFpUQWc3dH…
BIOX|Bioceres Crop Solutions Corp|Price:0.360|Chg%:+0.025 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9fU3pFbEtTbUNyX0ZpTk5WTW5HT3liU2RMay1ObWw3MERrN0VGTEtJYjUwbkNCYzdpLUk1YlAyU2dIUHRRSzlHdnVWaHA3RzhabEg1UDUtTmJfcGNCTnVFay1SelRyRUY0T1RvVjJR?oc=5" target="_blank">BIOX|Bioceres Crop …
Bioceres Crop Solutions (BIOX) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPYm5FUV85QS1La3dmWTJ1aGZ1QW0wTmNKTmVlZkhpTW5NX2dXM01BSDVkUHdnMUNoS0tscVhvMVBRM2hrN0QtZHZsY2VjTXZTLW5za2ZkcmF5WVQxeHVkVTEzZGpRcnp5TXNrYUhYTmh3Rm84c2doS0xVQThqRXZRT1hRUFF5TFpkOHZrTX…
Bioceres Crop Solutions Reports Fiscal Third Quarter 2026 Financial and Operational Results - Business Wire
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNS3IydndKMG9CX3JsY1hvUUFVcjg3anlTZWRuaVJlZ3BIUjFHOWNvcGpCRElEWENuVmNsb1g4RzB5YllJN0V6M2pjNmNEVXowZldaMnMwSFY1cVJ2VWpicDJEZENUSlk1c1ZmdENDV0M0aUR0RmJISXRjRmxBMVZNRmd3NnYtSDd0bTE0aT…
BIOX — Frequently Asked Questions
What is the current share price of BIOX?
As of 2026-08-05 17:25 PDT, BIOX trades at $0.36 on NASDAQ/NYSE. Its 52-week range is $0.32 to $3.59.
What is the market capitalisation of BIOX?
BIOX has a market capitalisation of $23.63M on NASDAQ/NYSE.
What is the P/E ratio of BIOX?
BIOX trades at a trailing price-to-earnings (P/E) ratio of -0.43. Its price-to-book (P/B) ratio is 0.09.
What is the return on equity (ROE) of BIOX?
BIOX has a return on equity (ROE) of -21.09%. Its return on capital employed (ROCE) is -0.18%.
Is BIOX a good stock to buy?
This page provides a data-driven analysis of BIOX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.